Background: There are concerns about the efficacy of antenatal corticosteroid treatment (ACT) in the growth-restricted fetus. Objective: To evaluate the effect of ACT on neurodevelopmental outcome at 2 years of corrected age according to the z score of birth head circumference (ZS HC) in a large prospective cohort of preterm infants. Methods: This study was conducted as a population-based, prospective, multicenter study, including 4,965 infants born between 24 and 33 weeks' gestation and whose status regarding ACT and the measurement of head circumference at birth were available. They were evaluated at 2 years of corrected age to assess neurological outcome. Three approaches were considered to estimate the effect of ACT on neurodevelopment: (i) logistic regression with adjustment on propensity score, (ii) weighted logistic regression using the inverse probability of treatment weighting method, and (iii) 1:1 matching of gestational age, ZS HC, and propensity score between treated and nontreated infants. Results: ACT was documented in 60% of infants. Three groups of infants were considered according to their ZS HC: between -3 and -1 standard deviation (SD), -1 and +1 SD, and +1 and +3 SD, respectively. ACT was associated with a significant improvement of neurodevelopmental outcome only for infants with an ZS HC of between +1 and +3 SD (adjusted OR 1.72; 95% CI 1.06-2.79). Moreover, ORs estimated in the -3 to -1 and +1 to +3 categories were significantly different. Conclusion: We found beneficial effects of ACT on neurodevelopmental outcomes at 2 years of corrected age only in preterm infants with a ZS HC >1 SD.

Keywords:
Neurodevelopment, Birth head circumference, Antenatal corticosteroid treatment, Preterm infants, Intrauterine growth restriction
1.
Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994;12:1-24.
2.
Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita ATN, Reddy UM, Saade GR, et al: Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016;374:1311-1320.
3.
Roberts D, Dalziel S: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006;3:CD004454.
4.
Sotiriadis A, Tsiami A, Papatheodorou S, Baschat AA, Sarafidis K, Makrydimas G: Neurodevelopmental outcome after a single course of antenatal steroids in children born preterm: a systematic review and meta-analysis. Obstet Gynecol 2015;125:1385-1396.
5.
Gascoin G, Flamant C: Long-term outcome in context of intra uterine growth restriction and/or small for gestational age newborns. J Gynécol Obstét Biol Reprod 2013;42:911-920.
6.
Guellec I, Lapillonne A, Renolleau S, Charlaluk M-L, Roze J-C, Marret S, et al: Neurologic outcomes at school age in very preterm infants born with severe or mild growth restriction. Pediatrics 2011;127:e883-e891.
7.
von Beckerath A-K, Kollmann M, Rotky-Fast C, Karpf E, Lang U, Klaritsch P: Perinatal complications and long-term neurodevelopmental outcome of infants with intrauterine growth restriction. Am J Obstet Gynecol 2013;208:130.e1-e6.
8.
Vidaeff AC, Blackwell SC: Potential risks and benefits of antenatal corticosteroid therapy prior to preterm birth in pregnancies complicated by severe fetal growth restriction. Obstet Gynecol Clin North Am 2011;38:205-214.
9.
Blickstein I: Antenatal corticosteroids: current controversies. J Perinat Med 2017;45:5-9.
10.
Morrison JL, Botting KJ, Soo PS, McGillick EV, Hiscock J, Zhang S, et al: Antenatal steroids and the IUGR fetus: are exposure and physiological effects on the lung and cardiovascular system the same as in normally grown fetuses? J Pregnancy 2012;2012:839656.
11.
Miller SL, Chai M, Loose J, Castillo-Meléndez M, Walker DW, Jenkin G, et al: The effects of maternal betamethasone administration on the intrauterine growth-restricted fetus. Endocrinology 2007;148:1288-1295.
12.
Ridout A, Watson H, Shennan A: Antenatal corticosteroids in perspective: rationalising current practice. BJOG 2016;123:1070.
13.
Chang YP: Evidence for adverse effect of perinatal glucocorticoid use on the developing brain. Korean J Pediatr 2014;57:101-109.
14.
Riskin-Mashiah S, Riskin A, Bader D, Kugelman A, Boyko V, Lerner-Geva L, et al: Antenatal corticosteroid treatment in singleton, small-for-gestational-age infants born at 24-31 weeks' gestation: a population-based study. BJOG 2016;123:1779-1786.
15.
Amiya RM, Mlunde LB, Ota E, Swa T, Oladapo OT, Mori R: Antenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis. PLoS One 2016;11: e0147604.
16.
Branger B, Rouger V, Berlie I, Beucher A, Flamant C, N'guyen The Tich S, et al: Monitoring network for vulnerable children in the Pays de la Loire (“Grandir ensemble” - Cohort LIFT): 10 years of activity 2003-2013. Arch Pediatr 2015;22:171-180.
17.
Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS: New intrauterine growth curves based on United States data. Pediatrics 2010;125:e214-e224.
18.
Brunet O, Lézine I, Josse D (eds): Manuel BLR-C: Brunet-Lézine révisé: échelle de développement psychomoteur de la première enfance. Paris, EAP, 1997.
19.
Flamant C, Branger B, Nguyen The Tich S, de la Rochebrochard E, Savagner C, Berlie I, et al: Parent-completed developmental screening in premature children: a valid tool for follow-up programs. PLoS One 2011;6:e20004.
20.
D'Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
21.
Austin PC, Stuart EA: Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661-3679.
22.
Mitsiakos G, Kovacs L, Papageorgiou A: Are antenatal steroids beneficial to severely growth restricted fetuses? J Matern Fetal Neonatal Med 2013;26:1496-1499.
23.
Ishikawa H, Miyazaki K, Ikeda T, Murabayashi N, Hayashi K, Kai A, et al: The effects of antenatal corticosteroids on short- and long-term outcomes in small-for-gestational-age infants. Int J Med Sci 2015;12:295-300.
24.
Boghossian NS, McDonald SA, Bell EF, Carlo WA, Brumbaugh JE, Stoll BJ, et al: Association of antenatal corticosteroids with mortality, morbidity, and neurodevelopmental outcomes in extremely preterm multiple gestation infants. JAMA Pediatr 2016;170:593-601.
25.
Schaap AH, Wolf H, Bruinse HW, Smolders-De Haas H, Van Ertbruggen I, Treffers PE: Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol 2001;97:954-960.
26.
Kamath-Rayne BD, Rozance PJ, Goldenberg RL, Jobe AH: Antenatal corticosteroids beyond 34 weeks gestation: what do we do now? Am J Obstet Gynecol 2016;215:423-430.
27.
Melamed N, Shah J, Yoon EW, Pelausa E, Lee SK, Shah PS, et al: The role of antenatal corticosteroids in twin pregnancies complicated by preterm birth. Am J Obstet Gynecol 2016;215:482.e1-e9.
28.
Wapner RJ, Gyamfi-Bannerman C, Thom EA; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network: What we have learned about antenatal corticosteroid regimens. Semin Perinatol 2016;40:291-297.
29.
Vidaeff AC, Belfort MA, Steer PJ: Antenatal corticosteroids: a time for more careful scrutiny of the indications? BJOG 2016;123:1067-1069.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.